Relapsed and refractory hodgkin lymphoma

Bastian von Tresckow, Craig Moskowitz

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed or refractory Hodgkin lymphoma (HL). This is based on two randomized controlled studies that showed better event-free survival (EFS) in those treated with ASCT as compared to standard-dose salvage chemotherapy. Several risk factors have been identified in HL patients receiving HDCT and ASCT including time to recurrence of HL, stage at relapse, and response to salvage therapy (SC) before HDCT. More recently, pre-ASCT positron emission tomography has been established as a powerful prognostic tool in relapsed HL. Patients with recurrent HL receive SC before the final myeloablative HDCT by default. However, neither SC nor HDCT regimens have thus far been compared in randomized trials so that the treating clinician has the choice between different regimens. In addition, radiotherapy before, during, and after ASCT as well as tandem ASCT was evaluated to improve the prognosis. So far, there is no role for maintenance therapy in this setting, but a phase III randomized placebo-controlled trial using brentuximab vedotin as maintenance therapy has been fully recruited and results are pending. Other ongoing trials incorporate new drugs into the SC regimens to increase the cure rates. Currently, allogeneic transplant is an option only for a small minority of relapsed/refractory HL patients.

Original languageEnglish (US)
Title of host publicationHodgkin Lymphoma
Subtitle of host publicationA Comprehensive Overview, Second Edition
PublisherSpringer International Publishing
Pages321-330
Number of pages10
ISBN (Electronic)9783319125053
ISBN (Print)9783319125046
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Hodgkin Disease
Drug Therapy
Recurrence
Salvage Therapy
Positron-Emission Tomography
Disease-Free Survival
Radiotherapy
Therapeutics
Randomized Controlled Trials
Placebos
Transplants
Pharmaceutical Preparations

Keywords

  • Brentuximab vedotin
  • Hodgkin lymphoma
  • PET
  • Refractory
  • Relapse
  • Transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

von Tresckow, B., & Moskowitz, C. (2015). Relapsed and refractory hodgkin lymphoma. In Hodgkin Lymphoma: A Comprehensive Overview, Second Edition (pp. 321-330). Springer International Publishing. https://doi.org/10.1007/978-3-319-12505-3-19

Relapsed and refractory hodgkin lymphoma. / von Tresckow, Bastian; Moskowitz, Craig.

Hodgkin Lymphoma: A Comprehensive Overview, Second Edition. Springer International Publishing, 2015. p. 321-330.

Research output: Chapter in Book/Report/Conference proceedingChapter

von Tresckow, B & Moskowitz, C 2015, Relapsed and refractory hodgkin lymphoma. in Hodgkin Lymphoma: A Comprehensive Overview, Second Edition. Springer International Publishing, pp. 321-330. https://doi.org/10.1007/978-3-319-12505-3-19
von Tresckow B, Moskowitz C. Relapsed and refractory hodgkin lymphoma. In Hodgkin Lymphoma: A Comprehensive Overview, Second Edition. Springer International Publishing. 2015. p. 321-330 https://doi.org/10.1007/978-3-319-12505-3-19
von Tresckow, Bastian ; Moskowitz, Craig. / Relapsed and refractory hodgkin lymphoma. Hodgkin Lymphoma: A Comprehensive Overview, Second Edition. Springer International Publishing, 2015. pp. 321-330
@inbook{08e87082a7854259aa84308e74b47d3d,
title = "Relapsed and refractory hodgkin lymphoma",
abstract = "High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed or refractory Hodgkin lymphoma (HL). This is based on two randomized controlled studies that showed better event-free survival (EFS) in those treated with ASCT as compared to standard-dose salvage chemotherapy. Several risk factors have been identified in HL patients receiving HDCT and ASCT including time to recurrence of HL, stage at relapse, and response to salvage therapy (SC) before HDCT. More recently, pre-ASCT positron emission tomography has been established as a powerful prognostic tool in relapsed HL. Patients with recurrent HL receive SC before the final myeloablative HDCT by default. However, neither SC nor HDCT regimens have thus far been compared in randomized trials so that the treating clinician has the choice between different regimens. In addition, radiotherapy before, during, and after ASCT as well as tandem ASCT was evaluated to improve the prognosis. So far, there is no role for maintenance therapy in this setting, but a phase III randomized placebo-controlled trial using brentuximab vedotin as maintenance therapy has been fully recruited and results are pending. Other ongoing trials incorporate new drugs into the SC regimens to increase the cure rates. Currently, allogeneic transplant is an option only for a small minority of relapsed/refractory HL patients.",
keywords = "Brentuximab vedotin, Hodgkin lymphoma, PET, Refractory, Relapse, Transplantation",
author = "{von Tresckow}, Bastian and Craig Moskowitz",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-12505-3-19",
language = "English (US)",
isbn = "9783319125046",
pages = "321--330",
booktitle = "Hodgkin Lymphoma",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Relapsed and refractory hodgkin lymphoma

AU - von Tresckow, Bastian

AU - Moskowitz, Craig

PY - 2015/1/1

Y1 - 2015/1/1

N2 - High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed or refractory Hodgkin lymphoma (HL). This is based on two randomized controlled studies that showed better event-free survival (EFS) in those treated with ASCT as compared to standard-dose salvage chemotherapy. Several risk factors have been identified in HL patients receiving HDCT and ASCT including time to recurrence of HL, stage at relapse, and response to salvage therapy (SC) before HDCT. More recently, pre-ASCT positron emission tomography has been established as a powerful prognostic tool in relapsed HL. Patients with recurrent HL receive SC before the final myeloablative HDCT by default. However, neither SC nor HDCT regimens have thus far been compared in randomized trials so that the treating clinician has the choice between different regimens. In addition, radiotherapy before, during, and after ASCT as well as tandem ASCT was evaluated to improve the prognosis. So far, there is no role for maintenance therapy in this setting, but a phase III randomized placebo-controlled trial using brentuximab vedotin as maintenance therapy has been fully recruited and results are pending. Other ongoing trials incorporate new drugs into the SC regimens to increase the cure rates. Currently, allogeneic transplant is an option only for a small minority of relapsed/refractory HL patients.

AB - High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is the standard treatment for patients with relapsed or refractory Hodgkin lymphoma (HL). This is based on two randomized controlled studies that showed better event-free survival (EFS) in those treated with ASCT as compared to standard-dose salvage chemotherapy. Several risk factors have been identified in HL patients receiving HDCT and ASCT including time to recurrence of HL, stage at relapse, and response to salvage therapy (SC) before HDCT. More recently, pre-ASCT positron emission tomography has been established as a powerful prognostic tool in relapsed HL. Patients with recurrent HL receive SC before the final myeloablative HDCT by default. However, neither SC nor HDCT regimens have thus far been compared in randomized trials so that the treating clinician has the choice between different regimens. In addition, radiotherapy before, during, and after ASCT as well as tandem ASCT was evaluated to improve the prognosis. So far, there is no role for maintenance therapy in this setting, but a phase III randomized placebo-controlled trial using brentuximab vedotin as maintenance therapy has been fully recruited and results are pending. Other ongoing trials incorporate new drugs into the SC regimens to increase the cure rates. Currently, allogeneic transplant is an option only for a small minority of relapsed/refractory HL patients.

KW - Brentuximab vedotin

KW - Hodgkin lymphoma

KW - PET

KW - Refractory

KW - Relapse

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84955734174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955734174&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-12505-3-19

DO - 10.1007/978-3-319-12505-3-19

M3 - Chapter

SN - 9783319125046

SP - 321

EP - 330

BT - Hodgkin Lymphoma

PB - Springer International Publishing

ER -